GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Klotho Neurosciences Inc (NAS:KLTO) » Definitions » Notes Receivable

KLTO (Klotho Neurosciences) Notes Receivable : $0.00 Mil (As of Mar. 2025)


View and export this data going back to 2024. Start your Free Trial

What is Klotho Neurosciences Notes Receivable?

Klotho Neurosciences's Notes Receivable for the quarter that ended in Mar. 2025 was $0.00 Mil.


Klotho Neurosciences Notes Receivable Historical Data

The historical data trend for Klotho Neurosciences's Notes Receivable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Klotho Neurosciences Notes Receivable Chart

Klotho Neurosciences Annual Data
Trend Dec21 Dec22 Dec23 Dec24
Notes Receivable
- - - -

Klotho Neurosciences Quarterly Data
Dec21 Jun22 Dec22 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Notes Receivable Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only - - - - -

Klotho Neurosciences Notes Receivable Calculation

Notes Receivable is an unconditional promise to receive a definite sum of money at a future date(s) within one year of the balance sheet date or the normal operating cycle, whichever is longer.


Klotho Neurosciences Notes Receivable Related Terms

Thank you for viewing the detailed overview of Klotho Neurosciences's Notes Receivable provided by GuruFocus.com. Please click on the following links to see related term pages.


Klotho Neurosciences Business Description

Traded in Other Exchanges
N/A
Address
13576 Walnut Street, Suite A, Omaha, NE, USA, 68144
Klotho Neurosciences Inc is in the development of essential medicines for the treatment of chronic diseases: Cancer, Cardiovascular, and Neurodegenerative disorders. The Company currently has acquired two licensed platforms: a generic drug portfolio and a biosimilar biologics platform that uses biologic therapies to treat cancer, and a proprietary, patented gene therapy platform which uses a gene therapy approach to introduce a therapeutic protein called Klotho inside the body to treat neurodegenerative diseases. Company pipeline includes KLTO 101, KLTO 202, KLTO 301.